Lowest Price Guaranteed From USD 4,799
Published
August 2022
Pages
1180
View Count
63832
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The cell therapies market is estimated to be worth $3.5 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 23.0% during the forecast period. Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.
Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates. Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.
Several recent developments have taken place in the field of cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2022-2035 report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The table below highlights various market segmentations done in the report.
Report Attribute | Details | |
Forecast Period |
2022 – 2035 |
|
Type of Therapy |
CAR-T therapy, TCR therapy, TIL therapy | |
Target Indications |
ALL, bladder cancer, cervical carcinoma, CLL, head and neck cancer, lung cancer, melanoma, multiple myeloma, NHL, ovarian cancer, sarcoma, others | |
Target Antigens |
CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC2 | |
Key Players |
Altor Bioscience, Novartis, GlaxoSmithKline / Adaptimmune Therapeutics / Merck, Juno Therapeutics / Celgene / WuXi AppTec, Gilead Sciences | |
Key Geographical Regions |
North America, Europe, Asia-Pacific, MENA, Latin America, Rest of the World | |
Key Geographical Regions | North America (US and Canada), Europe (UK, France, Germany, Spain, Italy, Rest of EU) and Asia-Pacific (Japan and Australia) | |
Key Companies Profiled | Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies, Lansion Biotechnology, Bavarian Nordic and Emergent BioSolutions | |
Customization Scope | 15% Free Customization Option | |
PowerPoint Presentation (Complimentary) | Available | |
Excel Data Packs (Complimentary) | Market Landscape Analysis, Product Competitiveness Analysis, Partnership and Collaboration Analysis, Grant Analysis, Publication Analysis, Porter's Five Forces Analysis, Market Forecast an Opportunity Analysis |
Amongst other elements, the report features the following:
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several relevant parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America, Europe, Asia Pacific, Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.
Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.
Chapter 4 includes detailed assessment of the current market landscape of more than 970 CAR-T cell therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
Chapter 5 includes detailed assessment of the current market landscape of more than 190 TCR-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome and nasopharyngeal carcinoma), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso and HLA), source of T-cells (autologous and allogeneic), route of administration (intravenous and intratumoral), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TCR-based therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
Chapter 6 includes detailed assessment of current market landscape of more than 75 TIL-based therapies that are currently in different stages of development. Additionally, it features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (phase III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic areas (oncological disorders, non-oncological disorders), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer and squamous cell carcinoma), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dose frequency (single dose and multiple doses), patient segment (children, adults, and seniors), and type of therapy (monotherapy and combination therapy). Further, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TIL-based therapies. The chapter also features an analyses on the developers landscape based on some relevant parameters, including year of establishment, company size (in terms of number of employees), and location of headquarters (North America, Europe and Asia-Pacific).
Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
Chapter 8 presents a detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TILs, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
Chapter 9 presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Chapter 10 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 11 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 12 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 13 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
Chapter 14 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.
Chapter 15 provides details on the various investments and grants that have been awarded to several stakeholders focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
Chapter 16 provides an in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
Chapter 17 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.
Chapter 18 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.
Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.
Chapter 20 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for T-cell products that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).
Chapter 21 highlights the key promotional strategies that are being implemented by the developers of the approved CAR-T Cell therapies (Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™) and TCR-based therapies (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 22 includes brief company profiles of the leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Former Chief Executive Officer, Cell Therapies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics, Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Former Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).
Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.7. Challenges Associated with Use of CAR-T Cell Therapies
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. Development History
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR Therapy
3.8.4. Comparison of CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. Development History
3.9.2. Development of TILs Therapy
3.10. Key Benefits and Roadblocks
3.11. Concluding Remarks
4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indications
4.2.6. Analysis by Key Target Antigens
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies
4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. TCR-BASED THERAPIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Phase of Development and Therapeutic Area
5.2.5. Analysis by Key Target Indication
5.2.6. Analysis by Key Target Antigen
5.2.7. Analysis by Source of T-Cells
5.2.8. Analysis by Route of Administration
5.2.9. Analysis by Phase of Development and Route of Administration
5.2.10. Analysis by Dosing Frequency
5.2.11. Analysis by Target Patient Segment
5.2.12. Analysis by Type of Therapy
5.2.13. Analysis by Phase of Development and Type of Therapy
5.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
5.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies
5.3. TCR-based Therapies: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
6. TIL-BASED THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
6.2.1. Analysis by Type of Developer
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Key Target Indication
6.2.5. Analysis by Source of T-Cells
6.2.6. Analysis by Route of Administration
6.2.7. Analysis by Dosing Frequency
6.2.8. Analysis by Target Patient Segment
6.2.9. Analysis by Type of Therapy
6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
6.3. TIL-based Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors
7.3. T-Cell Immunotherapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Co-Stimulatory Domain
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis by Trial Phase and Enrolled Patient Population
8.3.7. Analysis by Target Patient Segment
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.3.13. Analysis of Clinical Trials by Geography
8.3.14. Analysis of Enrolled Patient Population by Geography
8.4. TCR-based Therapies: Clinical Trial Analysis
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.4.3. Analysis by Trial Status
8.4.4. Analysis by Trial Registration Year and Trial Status
8.4.5. Analysis by Trial Phase
8.4.6. Analysis by Trial Phase and Enrolled Patient Population
8.4.7. Analysis by Target Patient Segment
8.4.8. Analysis by Type of Sponsor / Collaborator
8.4.9. Analysis by Study Design
8.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.4.13. Analysis of Clinical Trials by Geography
8.4.14. Analysis of Enrolled Patient Population by Geography
8.5. TIL-based Therapies: Clinical Trial Analysis
8.5.1. Analysis by Trial Registration Year
8.5.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.5.3. Analysis by Trial Status
8.5.4. Analysis by Trial Registration Year and Trial Status
8.5.5. Analysis by Trial Phase
8.5.6. Analysis by Trial Phase and Enrolled Patient Population
8.5.7. Analysis by Target Patient Segment
8.5.8. Analysis by Type of Sponsor / Collaborator
8.5.9. Analysis by Study Design
8.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.5.13. Analysis of Clinical Trials by Geography
8.5.14. Analysis of Enrolled Patient Population by Geography
9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Qualification
9.4.4. Analysis by Geographical Location of KOLs
9.4.5. KOL Activeness versus KOL Strength
9.4.6. Most Prominent KOLs: Analysis by RA score
9.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.5. TCR-based Therapies: Key Opinion Leaders
9.5.1. Analysis by Type of Organization
9.5.2. Analysis by Affiliated Organization
9.5.3. Analysis by Qualification
9.5.4. Analysis by Geographical Location of KOLs
9.5.5. KOL Activeness versus KOL Strength
9.5.6. Most Prominent KOLs: Analysis by RA score
9.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.6. TIL-based Therapies: Key Opinion Leaders
9.6.1. Analysis by Type of Organization
9.6.2. Analysis by Affiliated Organization
9.6.3. Analysis by Qualification
9.6.4. Analysis by Geographical Location of KOLs
9.6.5. KOL Activeness versus KOL Strength
9.6.6. Most Prominent KOLs: Analysis by RA score
9.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
10. CAR-T CELL THERAPY PROFILES
10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
10.2.1. Therapy Overview
10.2.2. Clinical Trial Information
10.2.3. Clinical Trial Endpoints
10.2.4. Clinical Trial Results
10.2.5. Estimated Sales Revenues
10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
10.3.1. Therapy Overview
10.3.2. Clinical Trial Information
10.3.3. Clinical Trial Endpoints
10.3.4. Clinical Trial Results
10.3.5. Estimated Sales Revenues
10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
10.4.1. Therapy Overview
10.4.2. Clinical Trial Information
10.4.3. Clinical Trial Endpoints
10.4.4. Clinical Trial Results
10.4.5. Estimated Sales Revenues
10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
10.5.1. Therapy Overview
10.5.2. Clinical Trial Information
10.5.3. Clinical Trial Endpoints
10.5.4. Clinical Trial Results
10.5.5. Estimated Sales Revenues
10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
10.6.1. Therapy Overview
10.6.2. Clinical Trial Information
10.6.3. Clinical Trial Endpoints
10.6.4. Clinical Trial Results
10.6.5. Estimated Sales Revenues
10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
10.7.1. Therapy Overview
10.7.2. Clinical Trial Information
10.7.3. Clinical Trial Endpoints
10.7.4. Clinical Trial Results
10.7.5. Estimated Sales Revenues
10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
10.8.1. Therapy Overview
10.8.2. Clinical Trial Information
10.8.3. Clinical Trial Endpoints
10.8.4. Clinical Trial Results
10.8.5. Estimated Sales Revenues
10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
10.9.1. Therapy Overview
10.9.2. Clinical Trial Information
10.9.3. Clinical Trial Endpoints
10.9.4. Estimated Sales Revenues
10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
10.10.1. Therapy Overview
10.10.2. Clinical Trial Information
10.10.3. Clinical Trial Endpoints
10.10.4. Clinical Trial Results
10.10.5. Estimated Sales Revenues
10.11. AUTO3 / CD19/22 CAR-T (Autolus)
10.11.1. Therapy Overview
10.11.2. Clinical Trial Information
10.11.3. Clinical Trial Endpoints
10.11.4. Clinical Trial Results
10.11.5. Estimated Sales Revenues
11. TCR-BASED THERAPY PROFILES
11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
11.2.1. Therapy Overview
11.2.2. Clinical Trial Information
11.2.3. Clinical Trial Endpoints
11.2.4. Clinical Trial Results
11.2.5. Estimated Sales Revenues
11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
11.3.1. Therapy Overview
11.3.2. Clinical Trial Information
11.3.3. Clinical Trial Endpoints
11.3.4. Clinical Trial Results
11.3.5. Estimated Sales Revenues
11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
11.4.1. Therapy Overview
11.4.2. Clinical Trial Information
11.4.3. Clinical Trial Endpoints
11.4.4. Clinical Trial Results
11.4.5. Estimated Sales Revenues
11.5. JTCR016 (Juno Therapeutics)
11.5.1. Therapy Overview
11.5.2. Clinical Trial Information
11.5.3. Clinical Trial Endpoints
11.5.4. Estimated Sales Revenues
11.6. TBI-1301 (Takara Bio)
11.6.1. Therapy Overview
11.6.2. Clinical Trial Information
11.6.3. Clinical Trial Endpoints
11.6.4. Clinical Trial Results
11.6.5. Estimated Sales Revenues
11.7. MDG1011 (Medigene)
11.7.1. Therapy Overview
11.7.2. Clinical Trial Information
11.7.3. Clinical Trial Endpoints
11.7.4. Clinical Trial Results
11.7.5. Estimated Sales Revenues
12. TIL-BASED THERAPY PROFILES
12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
12.2.1. Therapy Overview
12.2.2. Clinical Trial Information
12.2.3. Clinical Trial Endpoints
12.2.4. Clinical Trial Results
12.2.5. Estimated Sales Revenues
12.3. LN-145 (Iovance Biotherapeutics)
12.3.1. Therapy Overview
12.3.2. Clinical Trial Information
12.3.3. Clinical Trial Endpoints
12.3.4. Clinical Trial Results
12.3.5. Estimated Sales Revenues
12.4. ITIL-168 (Instil Bio)
12.4.1. Therapy Overview
12.4.2. Clinical Trial Information
12.4.3. Clinical Trial Endpoints
12.4.4. Clinical Trial Results
12.4.5. Estimated Sales Revenues
12.5. LTX-315 (Lytix Biopharma)
12.5.1. Therapy Overview
12.5.2. Clinical Trial Information
12.5.3. Clinical Trial Endpoints
12.5.4. Clinical Trial Results
12.5.5. Estimated Sales Revenues
13. EMERGING TECHNOLOGIES
13.1. Chapter Overview
13.2. Genome Editing Technologies
13.2.1. Technology Overview
13.2.2. Applications of Genome Editing Technologies
13.2.3. Emerging Technology Platforms for T-Cell Therapies
13.2.3.1. CRISPR / CAS9 System
13.2.3.1.1. Key Components
13.2.3.1.2. Mechanism of Action
13.2.3.1.3. Targeting Efficiency and Challenges
13.2.3.1.4. Next-Gen CRISPR Technology
13.2.3.1.5. Technology Providers
13.2.3.1.5.1. Intellia Therapeutics
13.2.3.1.5.2. Editas Medicine
13.2.3.1.5.3. CRISPR Therapeutics
13.2.3.1.5.4. Beam Therapeutics
13.2.3.1.5.5. Gracell Technologies
13.2.3.1.5.6. Caribou Biosciences
13.2.3.1.5.7. Nanjing Bioheng Biotech
13.2.3.1.5.8. Intima Biosciences
13.2.3.1.5.9. KSQ Therapeutics
13.2.3.1.5.10. Refuge Biotechnologies
13.2.3.2. TALENS
13.2.3.2.1. Key Components and Function
13.2.3.2.2. Mechanism of Action
13.2.3.2.3. Advantages and Challenges
13.2.3.2.4. Technology Providers
13.2.3.2.4.1. Cellectis
13.2.3.2.4.2. Editas Medicine
13.2.3.3. MegaTAL
13.2.3.3.1. Mechanism of Action
13.2.3.3.2. Technology Providers
13.2.3.3.2.1. bluebird bio
13.2.3.3.2.2. Precision Biosciences
13.2.3.4. Zinc Finger Nuclease
13.2.3.4.1. Mechanism of Action
13.2.3.4.2. Technology Providers
13.2.3.4.2.1. Sangamo Therapeutics
13.2.4. Competitive Analysis: Gene Editing Platforms
13.3. Designing T-Cell Therapies with Improved Characteristics
13.3.1. Technologies for Targeting Multiple Cancers
13.3.1.1. Antibody Coupled T-Cell Receptor
13.3.1.1.1. Cogent Biosciences
13.3.1.2. NKR-T Platform
13.3.1.2.1. Celyad
13.3.1.2.2. Glycostem
13.3.1.2.3. CatamaranBio
13.3.2. Technologies for Improved Safety
13.3.2.1. Armored CAR and EGFRt Technology
13.3.2.1.1. Juno Therapeutics
13.3.2.2. Rheoswitch Therapeutic System
13.3.2.2.1. Intrexon
13.3.2.2.2. Precigen
13.3.2.3. Inducible Caspase 9 Safety Switch
13.3.2.3.1. Bellicum Pharmaceuticals
13.3.2.3.1.1. CaspaCIDe Technology
13.3.2.3.1.2. CIDeCAR Technology
13.3.2.3.1.3. GoCAR-T Technology
13.3.2.4. On-OFF Switch, Multiple Companies
13.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
13.3.2.4.2. On-OFF Switch (Theravectys)
13.3.2.5. Other Technologies to Improve CAR-T Safety
13.3.3. Allogeneic Technologies
13.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
13.3.3.2. Allogeneic Platform (CELYAD)
13.3.3.3. Allogeneic Platform (Cellectis)
13.3.3.4. AlloCAR T (Allogene Therapeutics)
13.4. Future Perspectives
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Type of Product
14.3.4. Analysis by Year of Partnership and Type of Product
14.3.5. Analysis by Type of Partnership and Type of Product
14.3.6. Analysis by Type of Partner
14.3.7. Analysis by Type of Product and Type of Partner
14.3.8. Most Popular Products: Analysis by Number of Partnerships
14.3.9. Most Active Industry Players: Analysis by Number of Partnerships
14.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
14.3.11. Analysis by Geography
14.3.11.1. Intercontinental and Intracontinental Agreements
14.3.11.2. International and Local Deals
15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
15.3.1. Analysis of Instances by Year
15.3.2. Analysis of Amount Invested by Year
15.3.3. Analysis by Type of Funding
15.3.4. Analysis of Amount Invested across Different Types of Therapies
15.3.5. Analysis by Type of Investor
15.3.6. Most Active Players: Analysis by Number of Instances
15.3.7. Most Active Investors: Analysis by Amount Invested
15.3.8. Analysis of Amount Invested by Geography
15.3.9. Most Active Investors: Analysis by Number of Funding Instances
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
16.4.1. Analysis by Patent Publication Year
16.4.2. Analysis by Patent Application Year
16.4.3. Analysis by Geography
16.4.4. Analysis by Type of Player
16.4.5. Analysis by CPC Symbols
16.4.6. Analysis by Key Focus Area
16.4.7. Leading Players: Analysis by Number of Patents
16.4.8. Car-T Cell Therapies: Patent Benchmarking
16.4.9. Analysis By Patent Characteristics
16.4.10. Car-T Cell Therapies: Patent Valuation
16.5. TCR- based Therapies
16.5.1. Analysis by Patent Publication Year
16.5.2. Analysis By Patent Application Year
16.5.3. Analysis by Geography
16.5.4. Analysis by Type of Player
16.5.5. Analysis by CPC Symbols
16.5.6. Analysis by Key Focus Area
16.5.7. Leading Player: Analysis by Number of Patents
16.5.8. TCR-based Therapies: Patent Benchmarking
16.5.9. Analysis By Patent Characteristics
16.5.10. TCR-based Cell Therapies: Patent Valuation
16.6. TIL- based Therapies
16.6.1. Analysis by Patent Publication Year
16.6.2. Analysis By Patent Application Year
16.6.3. Analysis by Geography
16.6.4. Analysis by Type of Player
16.6.5. Analysis by CPC Symbols
16.6.6. Analysis by Key Focus Area
16.6.7. Leading Player: Analysis by Number of Patents
16.6.8. TIL-based Therapies: Patent Benchmarking
16.6.9. Analysis By Patent Characteristics
16.6.10. TIL-based Therapies: Patent Valuation
17. OTHER T-CELL IMMUNOTHERAPIES
17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
17.2.1. Fucosylated T-Cell Therapies
17.2.2. Gamma Delta T-Cell Therapies
17.2.3. PD-1 Knockout Engineered T-Cell Therapies
17.2.4. TAC T-Cell Therapies
17.2.5. T-Cell Vaccines
17.2.6. Treg Cell Therapies
17.2.7. Virus-Driven T-Cell Therapies
17.3. Other T-Cell Immunotherapies: Market Overview
17.3.1. Analysis by Type of T-Cell
17.3.2. Analysis by Source of T-Cell
17.3.3. Analysis by Phase of Development
17.3.4. Analysis by Therapeutic Area
17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks
18. CASE STUDY: CELL THERAPY MANUFACTURING
18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
18.3.1. Centralized Manufacturing Model
18.3.2. Decentralized Manufacturing Model
18.4. Scalability of Cell Therapy Manufacturing Processes
18.4.1. Scale-Up
18.4.2. Scale-Out
18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies
18.7. Important Factors for Cell Therapy Manufacturing
18.7.1. Characterization
18.7.2. Cost of Goods
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
19.3.1. Based on Associated Costs
19.3.2. Based on Availability of Competing Products
19.3.3. Based on Patient Segment
19.3.4. Based on Opinions of Industry Experts
19.4. Reimbursement related Considerations for T-Cell Immunotherapies
19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions And Forecast Methodology
20.4. Overall T-Cell Immunotherapy Market, 2022-2035
20.4.1. T-Cell Immunotherapy Market: Analysis by Type of Therapy
20.4.2. T-Cell Immunotherapy Market: Analysis by Target Indication
20.4.3. T-Cell Immunotherapy Market: Analysis by Target Antigen
20.4.4. T-Cell Immunotherapy Market: Analysis by Key Players
20.4.5. T-Cell Immunotherapy Market: Analysis by Geography
20.5. T-Cell Immunotherapy Market: Value Creation Analysis
20.6. Overall CAR-T Cell Therapies Market, 2022-2035
20.6.1. CAR-T Cell Therapies Market: Analysis by Target Indication
20.6.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
20.6.3. CAR-T Cell Therapies Market: Analysis by Key Players
20.6.4. CAR-T Cell Therapies Market: Analysis by Geography
20.6.5. Product Wise Sales Forecast
20.6.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
20.6.5.1.1. Sales Forecast (USD Million)
20.6.5.1.2. Net Present Value
20.6.5.1.3. Value Creation Analysis
20.6.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
20.6.5.2.1. Sales Forecast (USD Million)
20.6.5.2.2. Net Present Value (USD Million)
20.6.5.2.3. Value Creation Analysis
20.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
20.6.5.3.1. Sales Forecast (USD Million)
20.6.5.3.2. Net Present Value (USD Million)
20.6.5.3.3. Value Creation Analysis
20.6.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
20.6.5.4.1. Sales Forecast (USD Million)
20.6.5.4.2. Net Present Value (USD Million)
20.6.5.4.3. Value Creation Analysis
20.6.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
20.6.5.5.1. Sales Forecast (USD Million)
20.6.5.5.2. Net Present Value (USD Million)
20.6.5.5.3. Value Creation Analysis
20.6.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
20.6.5.6.1. Sales Forecast (USD Million)
20.6.5.6.2. Net Present Value (USD Million)
20.6.5.6.3. Value Creation Analysis
20.6.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
20.6.5.7.1. Sales Forecast (USD Million)
20.6.5.7.2. Net Present Value (USD Million)
20.6.5.7.3. Value Creation Analysis
20.6.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.8.1. Sales Forecast (USD Million)
20.6.5.8.2. Net Present Value (USD Million)
20.6.5.8.3. Value Creation Analysis
20.6.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
20.6.5.9.1. Sales Forecast (USD Million)
20.6.5.9.2. Net Present Value (USD Million)
20.6.5.9.3. Value Creation Analysis
20.6.5.10. Descartes-11 (Cartesian Therapeutics)
20.6.5.10.1. Sales Forecast (USD Million)
20.6.5.10.2. Net Present Value (USD Million)
20.6.5.10.3. Value Creation Analysis
20.6.5.11. Descartes-08 (Cartesian Therapeutics)
20.6.5.11.1. Sales Forecast (USD Million)
20.6.5.11.2. Net Present Value (USD Million)
20.6.5.11.3. Value Creation Analysis
20.6.5.12. Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine)
20.6.5.12.1. Sales Forecast (USD Million)
20.6.5.12.2. Net Present Value (USD Million)
20.6.5.12.3. Value Creation Analysis
20.6.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
20.6.5.13.1. Sales Forecast (USD Million)
20.6.5.13.2. Net Present Value (USD Million)
20.6.5.13.3. Value Creation Analysis
20.6.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
20.6.5.14.1. Sales Forecast (USD Million)
20.6.5.14.2. Net Present Value (USD Million)
20.6.5.14.3. Value Creation Analysis
20.6.5.15. TAK-007 (Takeda)
20.6.5.15.1. Sales Forecast (USD Million)
20.6.5.15.2. Net Present Value (USD Million)
20.6.5.15.3. Value Creation Analysis
20.6.5.16. AUTO1 (Autolus)
20.6.5.16.1. Sales Forecast (USD Million)
20.6.5.16.2. Net Present Value (USD Million)
20.6.5.16.3. Value Creation Analysis
20.6.5.17. AUTO3 (Autolus)
20.6.5.17.1. Sales Forecast (USD Million)
20.6.5.17.2. Net Present Value (USD Million)
20.6.5.17.3. Value Creation Analysis
20.6.5.18. CD19-CAR-T (Bioray Laboratories)
20.6.5.18.1. Sales Forecast (USD Million)
20.6.5.18.2. Net Present Value (USD Million)
20.6.5.18.3. Value Creation Analysis
20.6.5.19. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.19.1. Sales Forecast (USD Million)
20.6.5.19.2. Net Present Value (USD Million)
20.6.5.19.3. Value Creation Analysis
20.6.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
20.6.5.20.1. Sales Forecast (USD Million)
20.6.5.20.2. Net Present Value (USD Million)
20.6.5.20.3. Value Creation Analysis
20.6.5.21. CCT301 CAR-T (Shanghai PerHum Therapeutics)
20.6.5.21.1. Sales Forecast (USD Million)
20.6.5.21.2. Net Present Value (USD Million)
20.6.5.21.3. Value Creation Analysis
20.6.5.22. BinD19 (Shenzhen BinDeBio)
20.6.5.22.1. Sales Forecast (USD Million)
20.6.5.22.2. Net Present Value (USD Million)
20.6.5.22.3. Value Creation Analysis
20.6.5.23. CARCIK-CD19 (CoImmune)
20.6.5.23.1. Sales Forecast (USD Million)
20.6.5.23.2. Net Present Value (USD Million)
20.6.5.23.3. Value Creation Analysis
20.6.5.24. PBCAR269A (Precision BioSciences / Servier)
20.6.5.24.1. Sales Forecast (USD Million)
20.6.5.24.2. Net Present Value (USD Million)
20.6.5.24.3. Value Creation Analysis
20.6.5.25. CD123 CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.25.1. Sales Forecast (USD Million)
20.6.5.25.2. Net Present Value (USD Million)
20.6.5.25.3. Value Creation Analysis
20.6.5.26. BCMA CAR-T (Chongqing Precision Biotechnology)
20.6.5.26.1. Sales Forecast (USD Million)
20.6.5.26.2. Net Present Value (USD Million)
20.6.5.26.3. Value Creation Analysis
20.6.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.27.1. Sales Forecast (USD Million)
20.6.5.27.2. Net Present Value (USD Million)
20.6.5.27.3. Value Creation Analysis
20.6.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
20.6.5.28.1. Sales Forecast (USD Million)
20.6.5.28.2. Net Present Value (USD Million)
20.6.5.28.3. Value Creation Analysis
20.6.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
20.6.5.29.1. Sales Forecast (USD Million)
20.6.5.29.2. Net Present Value (USD Million)
20.6.5.29.3. Value Creation Analysis
20.6.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
20.6.5.30.1. Sales Forecast (USD Million)
20.6.5.30.2. Net Present Value (USD Million)
20.6.5.30.3. Value Creation Analysis
20.6.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
20.6.5.31.1. Sales Forecast (USD Million)
20.6.5.31.2. Net Present Value (USD Million)
20.6.5.31.3. Value Creation Analysis
20.6.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
20.6.5.32.1. Sales Forecast (USD Million)
20.6.5.32.2. Net Present Value (USD Million)
20.6.5.32.3. Value Creation Analysis
20.6.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
20.6.5.33.1. Sales Forecast (USD Million)
20.6.5.33.2. Net Present Value (USD Million)
20.6.5.33.3. Value Creation Analysis
20.6.5.34. CT053 (CARsgen Therapeutics)
20.6.5.34.1. Sales Forecast (USD Million)
20.6.5.34.2. Net Present Value (USD Million)
20.6.5.34.3. Value Creation Analysis
20.6.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
20.6.5.35.1. Sales Forecast (USD Million)
20.6.5.35.2. Net Present Value (USD Million)
20.6.5.35.3. Value Creation Analysis
20.6.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.36.1. Sales Forecast (USD Million)
20.6.5.36.2. Net Present Value (USD Million)
20.6.5.36.3. Value Creation Analysis
20.6.5.37. ALLO-605 (Allogene Therapeutics)
20.6.5.37.1. Sales Forecast (USD Million)
20.6.5.37.2. Net Present Value (USD Million)
20.6.5.37.3. Value Creation Analysis
20.6.5.38. WU CART 007 (Wugen)
20.6.5.38.1. Sales Forecast (USD Million)
20.6.5.38.2. Net Present Value (USD Million)
20.6.5.38.3. Value Creation Analysis
20.6.5.39. CT103A (Nanjing IASO Biotherapeutics)
20.6.5.39.1. Sales Forecast (USD Million)
20.6.5.39.2. Net Present Value (USD Million)
20.6.5.39.3. Value Creation Analysis
20.7. Overall TCR-based Therapies Market
20.7.1. TCR-Based Therapies Market: Analysis by Target Indication
20.7.2. TCR-Based Therapies Market: Analysis by Target Antigen
20.7.3. TCR-Based Therapies Market: Analysis by Key Players
20.7.4. TCR-Based Therapies Market: Analysis by Geography
20.7.5. Product Wise Sales Forecast
20.7.5.1 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore)
20.7.5.1.1. Sales Forecast (USD Million)
20.7.5.1.2. Net Present Value (USD Million)
20.7.5.1.3. Value Creation Analysis
20.7.5.2. GSK3377794 (GlaxoSmithKline)
20.7.5.2.1. Sales Forecast (USD Million)
20.7.5.2.2. Net Present Value (USD Million)
20.7.5.2.3. Value Creation Analysis
20.7.5.3. YT-E001 (China Immunotech)
20.7.5.3.1. Sales Forecast (USD Million)
20.7.5.3.2. Net Present Value (USD Million)
20.7.5.3.3. Value Creation Analysis
20.7.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
20.7.5.4.1. Sales Forecast (USD Million)
20.7.5.4.2. Net Present Value (USD Million)
20.7.5.4.3. Value Creation Analysis
20.7.5.5. EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma)
20.7.5.5.1. Sales Forecast (USD Million)
20.7.5.5.2. Net Present Value (USD Million)
20.7.5.5.3. Value Creation Analysis
20.7.5.6. NTLA-5001 (Intellia Therapeutics)
20.7.5.6.1. Sales Forecast (USD Million)
20.7.5.6.2. Net Present Value (USD Million)
20.7.5.6.3. Value Creation Analysis
20.7.5.7. TBI-1301 (Takara Bio)
20.7.5.7.1. Sales Forecast (USD Million)
20.7.5.7.2. Net Present Value (USD Million)
20.7.5.7.3. Value Creation Analysis
20.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
20.7.5.8.1. Sales Forecast (USD Million)
20.7.5.8.2. Net Present Value (USD Million)
20.7.5.8.3. Value Creation Analysis
20.7.5.9. FH-MCVA2TCR (TCRCure Biopharma)
20.7.5.9.1. Sales Forecast (USD Million)
20.7.5.9.2. Net Present Value (USD Million)
20.7.5.9.3. Value Creation Analysis
20.8. Overall TIL-Based Therapies Market
20.8.1. TIL-Based Therapies Market: Analysis by Target Indication
20.8.2. TIL-Based Therapies Market: Analysis by Key Players
20.8.3. TIL-Based Therapies Market: Analysis by Geography
20.8.3.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
20.8.3.1.1. Sales Forecast (USD Million)
20.8.3.1.2. Net Present Value (USD Million)
20.8.3.1.3. Value Creation Analysis
20.8.3.2. LN-145 (Iovance Biotherapeutics)
20.8.3.2.1. Sales Forecast (USD Million)
20.8.3.2.2. Net Present Value (USD Million)
20.8.3.2.3. Value Creation Analysis
20.8.3.3. LTX-315 and TILs (Lytix Biopharma)
20.8.3.3.1. Sales Forecast (USD Million)
20.8.3.3.2. Net Present Value (USD Million)
20.8.3.3.3. Value Creation Analysis
20.8.3.4. TILs (Prometheus Laboratories)
20.8.3.4.1. Sales Forecast (USD Million)
20.8.3.4.2. Net Present Value (USD Million)
20.8.3.4.3. Value Creation Analysis
20.8.3.5. Donor Lymphocyte Infusion (Incyte)
20.8.3.5.1. Sales Forecast (USD Million)
20.8.3.5.2. Net Present Value (USD Million)
20.8.3.5.3. Value Creation Analysis
20.8.3.6. ITIL-168 (Instil Bio)
20.8.3.6.1. Sales Forecast (USD Million)
20.8.3.6.2. Net Present Value (USD Million)
20.8.3.6.3. Value Creation Analysis
20.8.3.7. IOV-2001 (Iovance Biotherapeutics)
20.8.3.7.1. Sales Forecast (USD Million)
20.8.3.7.2. Net Present Value (USD Million)
20.8.3.7.3. Value Creation Analysis
20.8.3.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
20.8.3.8.1. Sales Forecast (USD Million)
20.8.3.8.2. Net Present Value (USD Million)
20.8.3.8.3. Value Creation Analysis
20.8.3.9. TILs (Bristol-Myers Squibb)
20.8.3.9.1. Sales Forecast (USD Million)
20.8.3.9.2. Net Present Value (USD Million)
20.8.3.9.3. Value Creation Analysis
21. PROMOTIONAL ANALYSIS
21.1. Chapter Overview
21.2. Channels Used for Promotional Campaigns
21.3. Summary of Product Website Analysis
21.4. Summary of Patient Support Services and Informative Downloads
21.5. Kymriah: Promotional Analysis
21.5.1. Drug Overview
21.5.2. Product Website Analysis
21.5.2.3. Informative Downloads
21.5.3. Patient Support Services
21.6. Yescarta: Promotional Analysis
21.6.1. Drug Overview
21.6.2. Product Website Analysis
21.6.2.3. Informative Downloads
21.6.3. Patient Support Services
21.7. Tecartus: Promotional Analysis
21.7.1. Drug Overview
21.7.2. Product Website Analysis
21.7.3. Patient Support Services
21.8. Breyanzi: Promotional Analysis
21.8.1. Drug Overview
21.8.2. Product Website Analysis
21.8.3. Patient Support Services
21.9. Abecma: Promotional Analysis
21.9.1. Drug Overview
21.9.2. Product Website Analysis
21.9.3. Patient Support Services
21.10. Carvykti: Promotional Analysis
21.10.1. Drug Overview
21.10.2. Product Website Analysis
21.10.3. Patient Support Services
21.11. Kimmtrak: Promotional Analysis
21.11.1. Drug Overview
21.11.2. Product Website Analysis
21.11.3. Patient Support Services
22. COMPANY PROFILES
22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Cell Therapies
24.2.1. Interview Transcript: Tim Oldham, Former Chief Executive Officer
24.3. Glycostem Therapeutics
24.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
24.4. Gracell Biotechnologies
24.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
24.5. Lion TCR
24.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
24.6. TxCell
24.6.1. Interview Transcript: Miguel Forte, Chief Executive Officer
24.7. Kite Pharma
24.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
24.8. Celyad
24.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
24.9. Iovance Biotherapeutics
24.9.1. Interview Transcript: Peter Ho, Former Director, Process Development
24.10. Waisman Biomanufacturing
24.10.1. Interview Transcript: Brian Dattilo, Director, Business Development
24.11. Theravectys
24.11.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
24.12. Changhai Hospital
24.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
24.13. University of Colorado
24.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
25. APPENDIX 1: TABULATED DATA
26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary (CAR-T Cell Therapies): Overall Market Landscape
Figure 2.2 Executive Summary (CAR-T Cell Therapies): Clinical Trial Analysis
Figure 2.3 Executive Summary (CAR-T Cell Therapies): Key Opinion Leaders
Figure 2.4 Executive Summary (CAR-T Cell Therapies): Partnerships and Collaborations
Figure 2.5 Executive Summary (CAR-T Cell Therapies): Funding and Investments
Figure 2.6 Executive Summary (CAR-T Cell Therapies): Patent Analysis
Figure 2.7 Executive Summary (CAR-T Cell Therapies): Market Forecast and Opportunity Analysis
Figure 2.8 Executive Summary (TCR-based Therapies): Overall Market Landscape
Figure 2.9 Executive Summary (TCR-based Therapies): Clinical Trial Analysis
Figure 2.10 Executive Summary (TCR-based Therapies): Key Opinion Leaders
Figure 2.11 Executive Summary (TCR-based Therapies): Partnerships and Collaborations
Figure 2.12 Executive Summary (TCR-based Therapies): Funding and Investments
Figure 2.13 Executive Summary (TCR-based Therapies): Patent Analysis
Figure 2.14 Executive Summary (TCR-based Therapies): Market Forecast and Opportunity Analysis
Figure 2.15 Executive Summary (TIL-based Therapies): Overall Market Landscape
Figure 2.16 Executive Summary (TIL-based Therapies): Clinical Trial Analysis
Figure 2.17 Executive Summary (TIL-based Therapies): Key Opinion Leaders
Figure 2.18 Executive Summary (TIL-based Therapies): Partnerships and Collaborations
Figure 2.19 Executive Summary (TIL-based Therapies): Funding and Investments
Figure 2.20 Executive Summary (TIL-based Therapies): Patent Analysis
Figure 2.21 Executive Summary (TIL-based Therapies): Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Roadblocks
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigens
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 TCR-based Therapies: Distribution by Type of Developer
Figure 5.2 TCR-based Therapies: Distribution by Phase of Development
Figure 5.3 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 5.5 TCR-based Therapies: Distribution by Key Target Indication
Figure 5.6 TCR-based Therapies: Distribution by Key Target Antigen
Figure 5.7 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.8 TCR-based Therapies: Distribution by Route of Administration
Figure 5.9 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Figure 5.10 TCR-based Therapies: Distribution by Dosing Frequency
Figure 5.11 TCR-based Therapies: Distribution by Target Patient Segment
Figure 5.12 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.13 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Figure 5.14 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.15 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.16 TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 5.17 TCR-based Therapy Developers: Distribution by Company Size
Figure 5.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.19 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 TIL-based Therapies: Distribution by Type of Developer
Figure 6.2 TIL-based Therapies: Distribution by Phase of Development
Figure 6.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 6.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 6.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 6.6 TIL-based Therapies: Distribution by Route of Administration
Figure 6.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 6.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 6.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 6.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 6.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 6.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 TCR-based Therapies: Popular Targets in Hematological Malignancies
Figure 7.3 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.4 TCR-based Therapies: Popular Targets in Solid Tumors
Figure 7.5 CAR-Construction: Distribution by Generation of CAR
Figure 7.6 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.7 CAR-Construction: Distribution by Type of Virus Used
Figure 7.8 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.9 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Figure 8.3 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.4 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.6 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.9 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.13 CAR-T Cell Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.14 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.15 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.16 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.17 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.18 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.19 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.20 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.21 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 8.22 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.23 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.24 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.25 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.26 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.27 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.28 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.29 TCR-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.30 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.31 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.32 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.33 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.34 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.35 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Figure 8.36 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.37 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.38 TIL-based Therapies Clinical Trial Analysis: Distribution o by Trial Phase
Figure 8.39 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.40 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.41 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.42 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.43 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.44 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.45 TIL-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.46 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.47 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.48 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.49 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 9.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 9.4 CAR-T Cell Therapies: Distribution by Geographical Location of KOLs
Figure 9.5 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.8 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.10 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.11 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.12 TCR-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.13 TCR-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.14 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.15 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.16 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.17 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.18 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.19 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.20 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.21 TIL-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.22 TIL-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.23 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.24 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.25 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.26 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.27 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 10.1 Kymriah®: Estimated Sales Revenues
Figure 10.2 Yescarta®: Estimated Sales Revenues
Figure 10.3 Tecartus™: Estimated Sales Revenues
Figure 10.4 Breyanzi®: Estimated Sales Revenues
Figure 10.5 Abecma®: Estimated Sales Revenues
Figure 10.6 Carvykti®: Estimated Sales Revenues
Figure 10.7 Carteyva: Estimated Sales Revenues
Figure 10.8 TBI-1501: Estimated Sales Revenues
Figure 10.9 AUTO1: Estimated Sales Revenues
Figure 10.10 AUTO3: Estimated Sales Revenues
Figure 11.1 Kimmtrak®: Estimated Sales Revenues
Figure 11.2 GSK3377794: Estimated Sales Revenues
Figure 11.3 ADP-A2M4: Estimated Sales Revenues
Figure 11.4 JTCR016: Estimated Sales Revenues
Figure 11.5 TBI-1301: Estimated Sales Revenues
Figure 11.6 MDG1011: Estimated Sales Revenues
Figure 12.1 LN-144: Estimated Sales Revenues
Figure 12.2 LN-145: Estimated Sales Revenues
Figure 12.3 ITIL-168: Estimated Sales Revenues
Figure 12.4 LTX-315: Estimated Sales Revenues
Figure 13.1 Genome Editing Technologies: Applications
Figure 13.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 13.3 TALENS: Mechanism of Action
Figure 13.4 MegaTAL: Mechanism of Action
Figure 13.5 Zinc Finger Nuclease: Mechanism of Action
Figure 13.6 Competitiveness Analysis: Gene Editing Platforms
Figure 13.7 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 13.8 Cellectis: Properties of Enhanced T-Cell Platform
Figure 13.9 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 14.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.8 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Figure 14.9 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Figure 14.10 Most Popular Products: Distribution by Number of Partnerships
Figure 14.11 Most Active Industry Players: Distribution by Number of Partnerships
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 14.13 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 14.14 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 15.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 15.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 15.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 15.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 15.5 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 - 2022 (USD Million)
Figure 15.6 Funding and Investments: Distribution by Types of Investors
Figure 15.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 15.8 Most Active Players: Distribution by Number of Instances
Figure 15.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 15.10 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 15.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.3 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.4 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.5 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.6 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 16.7 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Figure 16.8 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Figure 16.9 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.10 CAR-T Cell Therapies Patent Analysis: Key Focus Area
Figure 16.11 Leading Industry Players: Distribution by Number of Patents
Figure 16.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 16.15 Patent Analysis: Distribution by Patent Age
Figure 16.14 CAR-T Therapies: Patent Valuation Analysis
Figure 16.15 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.16 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.17 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.18 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.19 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.20 TCR-based Therapies Patent Analysis: Distribution by Geography
Figure 16.21 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.22 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.23 TCR-based Therapies Patent Analysis: Key Focus Area
Figure 16.24 Leading Industry Players: Distribution by Number of Patents
Figure 16.25 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.26 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.27 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.28 Patent Analysis: Distribution by Patent Age
Figure 16.29 TCR-based Therapies: Patent Valuation Analysis
Figure 16.30 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.31 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.32 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.33 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.34 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.35 TIL-based Therapies Patent Analysis: Distribution by Geography
Figure 16.36 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.37 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.38 TIL-based Therapies Patent Analysis: Key Focus Area
Figure 16.39 Leading Industry Players: Distribution by Number of Patents
Figure 16.40 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.41 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.42 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.43 Patent Analysis: Distribution by Patent Age
Figure 16.44 TIL-based Therapies: Patent Valuation Analysis
Figure 17.1 Mechanism of Action of Gamma Delta T-Cells
Figure 17.2 Mechanism of Action of PD-1 Knockout Engineered T-Cell Therapies
Figure 17.3 Functions of Treg Cells
Figure 17.4 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Figure 17.7 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 17.5 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 17.6 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 18.1 Steps for Manufacturing Cell Therapies
Figure 18.2 Centralized Manufacturing: Process Model
Figure 18.3 Decentralized Manufacturing: Process Model
Figure 18.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 18.5 Cell Therapy: Challenges and Drivers
Figure 18.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 18.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 18.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 19.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 20.1 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Figure 20.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Figure 20.3 T-Cell Immunotherapy Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.4 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.5 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.7 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 20.8 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.9 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.10 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.11 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.12 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 20.13 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.14 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.15 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.16 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 20.17 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.18 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.19 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.22 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.23 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 20.24 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 20.25 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.26 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 20.27 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.28 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.29 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.30 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.31 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.32 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.33 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 20.34 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 20.35 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 20.36 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.37 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.38 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.39 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.40 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 20.41 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.42 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.43 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.44 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.45 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.46 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.47 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.48 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.49 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Figure 20.50 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.51 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.52 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.53 TCR-Based Therapies Market: Distribution by Target Antigen , 2025 and 2035 (USD Billion)
Figure 20.54 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.55 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.56 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 20.57 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 20.58 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 20.59 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.60 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.61 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.62 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.63 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.64 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.65 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.66 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.67 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Figure 20.68 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.69 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.70 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.71 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.72 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.73 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 20.74 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.75 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.76 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.77 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 21.1 Channels Used for Promotional Campaigns
Figure 21.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 21.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 21.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 21.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 21.6 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 21.7 Product Website Analysis: Yescarta®, Messages for Patients
Figure 21.8 Product Website Analysis: Yescarta®, Kite Konnect
Figure 21.9 Product Website Analysis: Yescarta®, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 21.10 Product Website Analysis: Tecartus™, Messages for Healthcare Professionals
Figure 21.11 Product Website Analysis: Tecartus™, Messages for Patients
Figure 21.12 Product Website Analysis: Tecartus™, Kite Konnect
Figure 21.13 Product Website Analysis: Breyanzi®, Messages for Healthcare Professional
Figure 21.14 Product Website Analysis: Breyanzi®, Messages for Patients
Figure 21.15 Product Website Analysis: Breyanzi®, Cell Therapy 360
Figure 21.16 Product Website Analysis: Abecma®, Messages for Healthcare Professional
Figure 21.17 Product Website Analysis: Abecma®, Messages for Patients
Figure 21.18 Product Website Analysis: Abecma®, Cell Therapy 360
Figure 21.19 Product Website Analysis: Carvykti®, Messages for Healthcare Professional
Figure 21.20 Product Website Analysis: Carvykti®, Messages for Patients
Figure 21.21 Product Website Analysis: Carvykti®, MyCARVYKTI
Figure 21.22 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 21.23 Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 21.24 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Key Opinion Leaders
Figure 23.4 Concluding Remarks: Partnerships and Collaborations
Figure 23.5 Concluding Remarks: Funding and Investments Analysis
Figure 23.6 Concluding Remarks: Patent Analysis
Figure 23.7 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9 CAR-T Cell and TCR-based Therapies: Key Differences
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 TCR-based Therapies: Clinical Pipeline
Table 5.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 5.3 TCR-based Therapies: Preclinical Pipeline
Table 5.4 List of TCR-based Developers,
Table 6.1 TIL-based Therapies: Clinical Pipeline
Table 6.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 6.3 TIL-based Therapies: Preclinical Pipeline
Table 6.4 List of TIL-based Developers
Table 7.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 10.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 10.2 Therapy Profile: Kymriah® (Novartis)
Table 10.3 Kymriah®: Clinical Trial Information
Table 10.4 Kymriah®: Clinical Trial Endpoints
Table 10.5 Kymriah®: Clinical Trial Results
Table 10.6 Therapy Profile: Yescarta® (Gilead Sciences)
Table 10.7 Yescarta®: Clinical Trial Information
Table 10.8 Yescarta®: Clinical Trial Endpoints
Table 10.9 Yescarta®: Clinical Trial Results
Table 10.10 Therapy Profile: Tecartus™ (Gilead Sciences)
Table 10.11 Tecartus™: Clinical Trial Information
Table 10.12 Tecartus™: Clinical Trial Endpoints
Table 10.13 Tecartus™: Clinical Trial Results
Table 10.14 Therapy Profile: Breyanzi® (Bristol Myers Squibb)
Table 10.15 Breyanzi®: Clinical Trial Information
Table 10.16 Breyanzi®: Clinical Trial Endpoints
Table 10.17 Breyanzi®: Clinical Trial Results
Table 10.18 Therapy Profile: Abecma® (Bristol Myers Squibb)
Table 10.19 Abecma®: Clinical Trial Information
Table 10.20 Abecma®: Clinical Trial Endpoints
Table 10.21 Abecma®: Clinical Trial Results
Table 10.22 Therapy Profile: Carvykti™ (Janssen)
Table 10.23 Carvykti™: Clinical Trial Information
Table 10.24 Carvykti™: Clinical Trial Endpoints
Table 10.25 Carvykti™: Clinical Trial Results
Table 10.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 10.27 Carteyva: Clinical Trial Information
Table 10.28 Carteyva: Clinical Trial Endpoints
Table 10.29 Carteyva: Clinical Trial Results
Table 10.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 10.31 TBI-1501: Clinical Trial Information
Table 10.32 TBI-1501: Clinical Trial Endpoints
Table 10.33 Therapy Profile: AUTO1 (Autolus)
Table 10.34 AUTO1: Clinical Trial Information
Table 10.35 AUTO1: Clinical Trial Endpoints
Table 10.36 AUTO1: Clinical Trial Results
Table 10.37 Therapy Profile: AUTO3 (Autolus)
Table 10.38 AUTO3: Clinical Trial Information
Table 10.39 AUTO3: Clinical Trial Endpoints
Table 10.40 AUTO3: Clinical Trial Results
Table 11.1 TCR Cell Therapies: List of Therapies Profiled
Table 11.2 Therapy Profile: Kimmtrak (Immunocore)
Table 11.3 Kimmtrak: Clinical Trial Information
Table 11.4 Kimmtrak: Clinical Trial Endpoints
Table 11.5 Kimmtrak: Clinical Trial Results
Table 11.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 11.7 GSK3377794: Clinical Trial Information
Table 11.8 GSK3377794: Clinical Trial Endpoints
Table 11.9 GSK3377794: Clinical Trial Results
Table 11.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 11.11 ADP-A2M4: Clinical Trial Information
Table 11.12 ADP-A2M4: Clinical Trial Endpoints
Table 11.13 ADP-A2M4: Clinical Trial Results
Table 11.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 11.15 JTCR016: Clinical Trial Information
Table 11.16 JTCR016: Clinical Trial Endpoints
Table 11.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 11.18 TBI-1301: Clinical Trial Information
Table 11.19 TBI-1301: Clinical Trial Endpoints
Table 11.20 TBI-1301: Clinical Trial Results
Table 11.21 Therapy Profile: MDG1011 (Medigene)
Table 11.22 MDG1011: Clinical Trial Information
Table 11.23 MDG1011: Clinical Trial Endpoints
Table 11.24 MDG1011: Clinical Trial Results
Table 12.1 TIL Cell Therapies: List of Therapies Profiled
Table 12.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 12.3 LN-144: Clinical Trial Information
Table 12.4 LN-144: Clinical Trial Endpoints
Table 12.5 LN-144: Clinical Trial Results
Table 12.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 12.7 LN-145: Clinical Trial Information
Table 12.8 LN-145: Clinical Trial Endpoints
Table 12.9 LN-145: Clinical Trial Results
Table 12.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 12.11 ITIL-168: Clinical Trial Information
Table 12.12 ITIL-168: Clinical Trial Endpoints
Table 12.13 ITIL-168: Clinical Trial Results
Table 12.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 12.15 LTX-315: Clinical Trial Information
Table 12.16 LTX-315: Clinical Trial Endpoints
Table 12.17 LTX-315: Clinical Trial Results
Table 13.1 Bellicum Pharmaceuticals: Key Switch Technologies
Table 13.2 Technologies For CAR-T Safety Enhancement
Table 14.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2022
Table 15.1 T-Cell Immunotherapies: Funding and Investments, 2000-2022
Table 15.2 T-Cell Immunotherapies: Summary of Investments
Table 16.1 CART-Cell Therapy Patent Analysis: Prominent CPC Symbols
Table 16.2 CART-Cell Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.3 CART-Cell Therapy Patent Analysis: List of Top CPC Symbols
Table 16.4 CART-Cell Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.5 CART-Cell Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.6 TCR-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.7 TCR-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.8 TCR-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.9 TCR-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.10 TCR-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.11 TIL-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.12 TIL-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.13 TIL-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.14 TIL-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.15 TIL-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.1 Characteristic Properties of Treg Cells
Table 17.2 Other T-Cell Immunotherapies: Therapy Candidate Pipeline
Table 18.1 Assessment Strategies for Different Manufacturing Processes
Table 18.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 18.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 19.1 Price of Marketed Gene / Cell Therapies
Table 19.2 Price of Marketed Targeted Drugs
Table 19.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 19.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 20.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 20.2 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Net Present Value (USD Million)
Table 20.3 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Value Creation Analysis (USD Million)
Table 20.4 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Net Present Value (USD Million)
Table 20.5 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.6 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Net Present Value (USD Million)
Table 20.7 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.8 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.9 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.10 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Net Present Value (USD Million)
Table 20.11 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Value Creation Analysis (USD Million)
Table 20.12 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.13 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.14 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 20.15 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 20.16 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.17 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 20.21 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 20.22 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.23 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.24 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.25 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.26 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 20.27 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 20.28 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 20.29 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 20.30 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 20.31 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 20.32 TAK-007 (Takeda): Net Present Value (USD Million)
Table 20.33 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 20.34 AUTO1 (Autolus): Net Present Value (USD Million)
Table 20.35 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 20.36 AUTO3 (Autolus): Net Present Value (USD Million)
Table 20.37 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 20.38 CD19-CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 20.39 CD19-CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 20.40 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.41 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.42 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 20.43 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 20.44 CCT301 CAR-T (Shanghai PerHum Therapeutics): Net Present Value (USD Million)
Table 20.45 CCT301 CAR-T (Shanghai PerHum Therapeutics): Value Creation Analysis (USD Million)
Table 20.46 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 20.47 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 20.48 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 20.49 CARCIK-CD19 (CoImmune): Value Creation Analysis (USD Million)
Table 20.50 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 20.51 PBCAR269A (Precision BioSciences / Servier): Value Creation Analysis (USD Million)
Table 20.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.54 BCMA CAR-T (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.55 BCMA CAR-T (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.57 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.58 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 20.59 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 20.60 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 20.61 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 20.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.63 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.64 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 20.65 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 20.66 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.67 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.69 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.70 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 20.71 CT053 (CARsgen Therapeutics)): Value Creation Analysis (USD Million)
Table 20.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.73 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.75 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.76 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.77 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.78 WU CART 007 (Wugen): Net Present Value (USD Million)
Table 20.79 WU CART 007 (Wugen): Value Creation Analysis (USD Million)
Table 20.80 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 20.81 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.82 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 20.83 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 20.84 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 20.85 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 20.86 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 20.87 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 20.88 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 20.89 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 20.90 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.91 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.92 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 20.93 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 20.94 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 20.95 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 20.96 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 20.97 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 20.98 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.99 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.100 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.101 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.102 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.103 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.104 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 20.105 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 20.106 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 20.107 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 20.108 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 20.109 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 20.110 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 20.111 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 20.112 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.113 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.114 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 20.115 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 20.116 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 20.117 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 21.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 21.2 Kymriah®: Drug Overview
Table 19.3 Yescarta®: Drug Overview
Table 21.4 Tecartus™: Drug Overview
Table 21.5 Breyanzi®: Drug Overview
Table 21.6 Abecma®: Drug Overview
Table 21.7 Carvykti™: Drug Overview
Table 21.8 Kimmtrak®: Drug Overview
Table 22.1 Leading T-Cell Immunotherapy Developers
Table 22.2 Adaptimmune Therapeutics: Company Profile
Table 22.3 Alaunos Therapeutics: Company Profile
Table 22.4 Autolus: Company Profile
Table 22.5 bluebird bio: Company Profile
Table 22.6 Bristol Myers Squibb: Company Profile
Table 22.7 CARsgen Therapeutics: Company Profile
Table 22.8 Cellectis: Company Profile
Table 22.9 Cellular Biomedicine Group: Company Profile
Table 22.10 Gilead Sciences: Company Profile
Table 22.11 GlaxoSmith Kline: Company Profile
Table 22.12 Immatics: Company Profile
Table 22.13 Immunocore: Company Profile
Table 22.14 Innovative Cellular Therapeutics: Company Profile
Table 22.15 Iovance Biotherapeutics: Company Profile
Table 22.16 Kuur Therapeutics: Company Profile
Table 22.17 Lion TCR: Company Profile
Table 22.18 Noile-Immune Biotech: Company Profile
Table 22.19 Novartis: Company Profile
Table 22.20 Shanghai Genechem: Company Profile
Table 22.21 Sinobioway Cell Therapy: Company Profile
Table 22.22 Takara Bio: Company Profile
Table 22.23 Wellington Zhaotai Therapies: Company Profile
Table 22.24 Zelluna Immunotherapy: Company Profile
Table 25.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 25.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 25.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 25.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Table 25.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Table 25.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 25.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Table 25.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 25.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 25.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 25.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Table 25.19 TCR-based Therapies: Distribution by Type of Developer
Table 25.20 TCR-based Therapies: Distribution by Phase of Development
Table 25.21 TCR-based Therapies: Distribution by Therapeutic Area
Table 25.22 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.23 TCR-based Therapies: Distribution by Key Target Indication
Table 25.24 TCR-based Therapies: Distribution by Key Target Antigen
Table 25.25 TCR-based Therapies: Distribution by Source of T-Cells
Table 25.26 TCR-based Therapies: Distribution by Route of Administration
Table 25.27 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Table 25.28 TCR-based Therapies: Distribution by Dosing Frequency
Table 25.29 TCR-based Therapies: Distribution by Target Patient Segment
Table 25.30 TCR-based Therapies: Distribution by Type of Therapy
Table 25.31 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Table 25.32 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Table 25.33 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Table 25.34 TCR-based Therapy Developers: Distribution by Year of Establishment
Table 25.35 TCR-based Therapy Developers: Distribution by Company Size
Table 25.36 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.37 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.38 TIL-based Therapies: Distribution by Type of Developer
Table 25.39 TIL-based Therapies: Distribution by Phase of Development
Table 25.40 TIL-based Therapies: Distribution by Therapeutic Area
Table 25.41 TIL-based Therapies: Distribution by Key Target Indications
Table 25.42 TIL-based Therapies: Distribution by Source of T-Cells
Table 25.43 TIL-based Therapies: Distribution by Route of Administration
Table 25.44 TIL-based Therapies: Distribution by Dosing Frequency
Table 25.45 TIL-based Therapies: Distribution by Target Patient Segment
Table 25.46 TIL-based Therapies: Distribution by Type of Therapy
Table 25.47 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Table 25.48 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 25.49 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 25.50 TIL-based Therapy Developers: Distribution by Company Size
Table 25.51 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.52 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.53 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Table 25.54 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.55 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.56 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.57 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.58 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.59 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.60 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.61 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.62 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.63 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.64 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.65 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.66 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.67 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.68 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-20172022
Table 25.69 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.70 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.71 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Table 25.72 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.73 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.74 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.75 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.76 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.77 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.78 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.79 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.80 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.81 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.82 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.83 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Table 25.84 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Table 25.85 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.86 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.87 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.88 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.89 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.90 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.91 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.92 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.93 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.94 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.95 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.96 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.97 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.98 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 25.99 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.100 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 25.101 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.102 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.103 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.104 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.105 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.106 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.107 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.108 TCR-based Therapies KOL Analysis: Distribution by Qualification
Table 25.109 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.110 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.111 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.112 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.113 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.114 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.115 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.116 TIL-based Therapies KOL Analysis: Distribution by Qualification
Table 25.117 TIL-based Therapies: Geographical Distribution of KOLs
Table 25.118 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.119 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.120 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.121 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.122 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.123 Kymriah®: Estimated Sales Revenues
Table 25.124 Yescarta®: Estimated Sales Revenues
Table 25.125 Tecartus™: Estimated Sales Revenues
Table 25.126 Breyanzi®: Estimated Sales Revenues
Table 25.127 Abecma®: Estimated Sales Revenues
Table 25.128 Carvykti®: Estimated Sales Revenues
Table 25.129 Carteyva: Estimated Sales Revenues
Table 25.130 TBI-1501: Estimated Sales Revenues
Table 25.131 AUTO1: Estimated Sales Revenues
Table 25.132 AUTO3: Estimated Sales Revenues
Table 25.133 Kimmtrak®: Estimated Sales Revenues
Table 25.134 GSK3377794: Estimated Sales Revenues
Table 25.135 ADP-A2M4: Estimated Sales Revenues
Table 25.136 JTCR016: Estimated Sales Revenues
Table 25.137 TBI-1301: Estimated Sales Revenues
Table 25.138 MDG1011: Estimated Sales Revenues
Table 25.139 LN-144: Estimated Sales Revenues
Table 25.140 LN-145: Estimated Sales Revenues
Table 25.141 ITIL-168: Estimated Sales Revenues
Table 25.142 LTX-315: Estimated Sales Revenues
Table 25.143 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 25.144 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.145 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.146 Partnerships and Collaborations: Distribution by Type of Product
Table 25.147 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Therapy
Table 25.148 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 25.149 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.150 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.151 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Table 25.152 Most Popular Products: Distribution by Number of Partnerships
Table 25.153 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.154 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.155 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 25.156 Partnerships and Collaborations: Distribution of International and Local Deals
Table 25.157 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 25.158 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 25.159 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 25.160 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.161 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 – 2022 (USD Million)
Table 25.162 Funding and Investments: Distribution by Types of Investors
Table 25.163 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 25.164 Most Active Players: Distribution by Number of Instances
Table 25.165 Most Active Players: Distribution by Amount Invested
Table 25.166 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 25.167 Most Active Investors: Distribution by Number of Funding Instances
Table 25.168 Patent Analysis: Distribution by Type of Patent
Table 25.169 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.170 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.171 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.172 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.173 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 25.174 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 25.175 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 25.176 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.177 Leading Industry Players: Distribution by Number of Patents
Table 25.178 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.179 Leading Patent Assignees: Distribution by Number of Patents
Table 25.180 Patent Analysis: Distribution by Patent Age
Table 25.181 CAR-T Therapies: Patent Valuation Analysis
Table 25.182 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.183 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.184 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.185 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.186 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Table 25.187 TCR-based Therapies Patent Analysis: Distribution by Geography
Table 25.188 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.189 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.190 Leading Industry Players: Distribution by Number of Patents
Table 25.191 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.192 Leading Patent Assignees: Distribution by Number of Patents
Table 25.193 Patent Analysis: Distribution by Patent Age
Table 25.194 TCR-based Therapies: Patent Valuation Analysis
Table 25.195 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.196 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.197 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.198 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.199 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted patents
Table 25.200 TIL-based Therapies Patent Analysis: Distribution by Geography
Table 25.201 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.202 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.203 Leading Industry Players: Distribution by Number of Patents
Table 25.204 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.205 Leading Patent Assignees: Distribution by Number of Patents
Table 25.206 Patent Analysis: Distribution by Patent Age
Table 25.207 TIL-based Therapies: Patent Valuation Analysis
Table 25.208 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Table 25.209 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 25.210 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 25.211 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 25.212 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Table 25.213 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Table 25.214 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Table 25.215 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035
Table 25.216 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.217 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.218 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Table 25.219 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.220 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.221 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.222 CAR-T Cell Therapies Market: Distribution by Target Geography, 2025 and 2035 (USD Billion)
Table 25.223 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Table 25.224 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.225 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.226 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.227 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Table 25.228 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.229 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.230 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.231 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Table 25.232 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.233 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.234 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Table 25.235 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Table 25.236 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.237 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Table 25.238 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.239 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.240 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.241 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.242 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast till 2035 (USD Million)
Table 25.243 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.244 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Table 25.245 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Table 25.246 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Table 25.247 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.248 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.249 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.250 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.251 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Table 25.252 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.253 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.254 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.255 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.256 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.257 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.258 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.259 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.260 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Table 25.261 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.262 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Table 25.263 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.264 TCR-Based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.265 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.266 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.267 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales
Table 25.268 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Table 25.269 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Table 25.270 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.271 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.272 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.273 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Table 25.274 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, 2035 (USD Million)
Table 25.275 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.276 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Table 25.277 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.278 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Table 25.279 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.280 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.281 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.282 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.283 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.284 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Table 25.285 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Table 25.286 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.287 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.288 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
The following companies and organizations have been mentioned in the report:
Source: www.cancer.org/research/cancer-facts-statistics/global.html